Mark Morais has served as Fortrea’s Chief Operations Officer and President, Clinical Development since May 2023. In this role, he is responsible for the strategy and delivery of Fortrea’s clinical operations inclusive of its full-service CRO, functional service provider offerings and therapeutic expansion. 

Mark brings more than two decades of experience in the CRO industry, including a successful track record in operational optimization and commercial development. Working closely with clients, he has helped shape the design of strategic alliances and preferred-provider relationships. Mark held a number of leadership positions at Labcorp Drug Development, prior to Fortrea’s spinoff from Labcorp. He served as President of Clinical Operations and Commercial Services from 2020 to 2023. Previous roles included Senior Vice President of Strategic Deal Development and Alliance Management, and Vice President of Strategic Deal Development and Pricing. Prior to joining Labcorp Drug Development, Mark served at Quintiles/IQVIA from 2001 to 2016, where he held global leadership positions in both Commercial Development and Clinical Operations. 

Mark received his bachelor's degree in Economics from North Carolina State University and has served multiple terms in on the Poole College of Management advisory board.

J. Stillman Hanson is General Counsel and has served in this position since Fortrea’s launch as an independent company in July 2023.

Stillman has more than two decades of legal experience in both private practice and in-house positions, serving as strategic business advisor and partner as well as counsel on legal, compliance and corporate governance matters. Prior to joining Labcorp, he served as General Counsel, Chief Compliance Officer and Corporate Secretary at G1 Therapeutics, Inc., a publicly traded biopharmaceutical company from 2018 to 2023. Before that, Stillman was Associate General Counsel and Vice President at IQVIA, a publicly traded healthcare services company from 2016 to 2018. Stillman served as Associate General Counsel at Quintiles from 2010 to 2016, where he participated in Quintiles’ initial public offering in 2013 and contributed to Quintiles merger with IMS Health to create QuintilesIMS in 2016. Prior to joining Quintiles, he practiced corporate and securities law at Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, LLP, a Raleigh, North Carolina law firm. 

Stillman earned his JD from the University of North Carolina School of Law and a bachelor's degree in Economics and History from Wake Forest University. He is admitted to the North Carolina State Bar.

John Doyle, DrPH, joined Fortrea as President, Consulting in October 2023. He leads a global team of expert consultants across the product development lifecycle, helping customers navigate complex and fast-changing business and regulatory environments. The team's solutions include clinical development and regulatory strategy, real-world evidence, market access, health economics and outcomes research (HEOR), medical writing and publishing, as well as specialist services, such as pediatric plan development and orphan drug designation. 

John brings more than three decades of extensive industry knowledge and experience to Fortrea along with a track record of building and operating differentiated consulting organizations that drive innovation and growth. John joined Fortrea from Exponent (NASDAQ: EXPO), a scientific and engineering consulting firm based in the Silicon Valley, where he led the Health Sciences business. Previously, John led the Global Healthcare Innovation Center at Pfizer (NYSE: PFE), focused on optimizing equitable and affordable access to Pfizer’s medicine and vaccines. While at Pfizer he spearheaded healthcare innovation programs incorporating digital health, data science and real-world evidence in customer collaborations. Earlier in his career, John served in senior advisory and leadership roles across the life-science industry, including IQVIA (NYSE: IQV), Analytica International, now owned by Certara (NASDAQ: CERT), and Bristol-Myers Squibb (NYSE: BMY). John is active in thought leadership in academia and industry. He has published more than 50 peer-reviewed papers and 100 conference abstracts. 

John earned Doctorate and Master of Public Health degrees in Epidemiology from the Columbia University Mailman School of Public Health and a Bachelor of Science degree in Business Management and Applied Economics with a concentration in the Life Sciences from Cornell University. He has served on the faculty at the Columbia University Mailman School of Public Health since 2005.